Peter S. Kim - 13 May 2024 Form 4/A - Amendment Insider Report for Entrada Therapeutics, Inc. (TRDA)

Reporting relationship: Director
Issuer ticker: TRDA
Reported as of: 13 May 2024
Net transaction value: +$731,682
SEC form: 4/A - Amendment
Accepted by SEC: 18 Jun 2025, 16:32:46 UTC
Original report date: 16 May 2024
Prior SEC filing: 10 May 2024
Next SEC filing: 16 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Jared Cohen, as Attorney-in-Fact

Key filing fact

Peter S. Kim filed Form 4/A - Amendment for Entrada Therapeutics, Inc. (TRDA) on 18 Jun 2025.

Key facts

This page summarizes Peter S. Kim's Form 4/A - Amendment filing for Entrada Therapeutics, Inc. (TRDA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Jun 2025, 16:32.

Change

Previous filing in this sequence was filed on 10 May 2024.
Current net transaction value: +$731,682.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001181180 Primary reporting owner

KIM PETER S

Relationship: Director
Address: C/O ENTRADA THERAPEUTICS, INC., ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Signature date: 18 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRDA transaction

Common Stock

Purchase

Transaction value: $367,010
Shares: +25,000
Change %: +37%
Price: $14.68
Shares after: 92,412
Date: 13 May 2024
Ownership: Direct
Footnotes: F1, F2

TRDA transaction

Common Stock

Purchase

Transaction value: $364,672
Shares: +25,000
Change %: +27%
Price: $14.59
Shares after: 117,412
Date: 14 May 2024
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.63 to $14.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Footnote F2

On May 16, 2024, the Reporting Person filed a Form 4 that reported the purchase of 25,000 shares of common stock on May 14, 2024 and inadvertently omitted to report the purchase of an additional 25,000 shares of common stock on May 13, 2024. This Form 4/A reports the purchase of those 25,000 additional shares of common stock and to correct certain totals.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.465 to $14.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.